Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PTPRC | P08575 | 2/20 | 0.30 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5397237 | 0.75 | CA1 (0.48) | ADRA2BALDH1A1 | |
| SCHEMBL5393586 | 0.75 | ALDH1A1 (0.50) | ALDH1A1GAAPTPRCCTDSP1 | |
| SCHEMBL21178029 | 0.70 | ALDH1A1 (0.41) | ALDH1A1GAA | |
| SCHEMBL10583512 | 0.69 | LTA4H (0.48) | ALDH1A1GAA | |
| SCHEMBL22877201 | 0.69 | MAPT (0.41) | ALDH1A1CTDSP1 | |
| SCHEMBL7045603 | 0.67 | NISCH (0.39) | ADRA2AADRA2BADRA2CALDH1A1NISCH | |
| SCHEMBL22762103 | 0.66 | TAAR1 (0.36) | ADRA2AADRA2BADRA2C | |
| SCHEMBL11196008 | 0.66 | CYSLTR2 (0.51) | ADRA2AALDH1A1 | |
| SCHEMBL699772 | 0.65 | ALDH1A1 (0.38) | ALDH1A1PTPRCCDC25B | |
| SCHEMBL898540 | 0.65 | ESR1 (0.50) | ADRA2AADRA2BADRA2CALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427550-B2 | 5-fluorouracil compounds | NUCORION PHARMACEUTICALS, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20200399227-A1 | 5-FLUOROURACIL COMPOUNDS | NUCORION PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
| WO-2019143860-A1 | 5-FLUOROURACIL COMPOUNDS | NUCORION PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399227-A1 | 5-FLUOROURACIL COMPOUNDS | DPYD, DHFR, FAU | ADRA2A 2748/4885ADRA2B 3262/4885ADRA2C 2446/4885 |
| US-11427550-B2 | 5-fluorouracil compounds | DPYD, DHFR, MTHFD1 | ADRA2A 3164/4885ADRA2B 3443/4885ADRA2C 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.